- Andelyn Biosciences has partnered with Amplo Biotechnology to provide scalable, clinical-grade AAV manufacturing for neuromuscular junction (NMJ) gene therapy programs.
- The collaboration will use Andelyn’s suspension AAV Curator® platform to support cGMP-compliant development and prepare therapies for clinical evaluation.
Andelyn Biosciences, a cell and gene therapy CDMO, has partnered with Amplo Biotechnology to enable scalable manufacturing of clinical-grade adeno-associated virus (AAV) material. The partnership targets neuromuscular junction (NMJ) disorders, which can cause severe muscle weakness and may require respiratory support or mobility aids in affected patients.
The collaboration will leverage Andelyn’s suspension AAV Curator® platform, a data-driven, scalable system designed to adapt and optimise processes for both clinical and commercial production. The platform provides a pathway to cGMP manufacturing, allowing Amplo Biotechnology to advance its gene therapy programs toward clinical trials while focusing on safety and efficacy.
Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, said: “Our Curator® platform and end-to-end capabilities are designed to help partners achieve key development and clinical milestones.”
Amplo Biotechnology highlighted that the partnership strengthens its ability to deliver high-quality AAV material and supports its mission to develop transformative therapies for families affected by genetic NMJ disorders worldwide.
Andelyn’s Columbus, Ohio, facilities provide end-to-end development and manufacturing capabilities, supporting both rare and prevalent gene therapies.
